These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14696560)

  • 21. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of combination abacavir + tenofovir + lamivudine (3TC).
    AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):104. PubMed ID: 19271334
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA notifications. Lamivudine/zidovudine combination approved for pediatric use.
    AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19938311
    [No Abstract]   [Full Text] [Related]  

  • 26. Generic lamivudine and abacavir approved.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043839
    [No Abstract]   [Full Text] [Related]  

  • 27. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focusing on the second phase of plasma HIV-1 RNA clearance.
    Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
    AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
    [No Abstract]   [Full Text] [Related]  

  • 29. Abacavir: new preparation. Risks limit the value.
    Prescrire Int; 2000 Jun; 9(47):67-9. PubMed ID: 11010740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.
    Hicks CB
    AIDS Clin Care; 2009 Jan; 21(1):3. PubMed ID: 19219957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 144-week data released on Gilead's study 934.
    AIDS Patient Care STDS; 2007 Aug; 21(8):603-4. PubMed ID: 17902243
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial).
    de Truchis P; Mathez D; Force G; Rouveix E; Khuong MA; Chemlal K; Thiaux C; Leibowitch J
    HIV Clin Trials; 2007; 8(2):102-4. PubMed ID: 17507326
    [No Abstract]   [Full Text] [Related]  

  • 33. Triple-nucleoside regimens versus efavirenz.
    De Luca A; Di Giambenedetto S
    N Engl J Med; 2004 Aug; 351(7):717-9; author reply 717-9. PubMed ID: 15306677
    [No Abstract]   [Full Text] [Related]  

  • 34. Conference report - antiretroviral therapy update from the 9th European AIDS Conference.
    Conway B
    MedGenMed; 2003 Dec; 5(4):30. PubMed ID: 14745377
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA notifications. Generic abacavir and lamivudine combo approved.
    AIDS Alert; 2008 Oct; 23(10):115. PubMed ID: 18935685
    [No Abstract]   [Full Text] [Related]  

  • 36. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meeting notes from ICAAC. NRTI-only regimens: making a comeback?
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):8-9. PubMed ID: 15717378
    [No Abstract]   [Full Text] [Related]  

  • 39. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.